Contrarius Group Holdings LTD Intellia Therapeutics, Inc. Transaction History
Contrarius Group Holdings LTD
- $2.21 Trillion
- Q3 2025
A detailed history of Contrarius Group Holdings LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Contrarius Group Holdings LTD holds 5,889,936 shares of NTLA stock, worth $51.2 Million. This represents 4.6% of its overall portfolio holdings.
Number of Shares
5,889,936
Previous 1,552,508
279.38%
Holding current value
$51.2 Million
Previous $14.6 Billion
598.5%
% of portfolio
4.6%
Previous 0.82%
Shares
4 transactions
Others Institutions Holding NTLA
# of Institutions
339Shares Held
98.4MCall Options Held
3.26MPut Options Held
1.55M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$104 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$96.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$83.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.02MShares$52.4 Million0.01% of portfolio
-
State Street Corp Boston, MA4.97MShares$43.2 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $661M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...